A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level
Parsanezhad, M.Ebrahim.; Alborzi, S.; Jahromi, B.Namavar.
International Journal of Fertility and Women's Medicine 47(6): 272-277
2003
ISSN/ISBN: 1534-892X PMID: 12570169 DOI: 10.1007/s00404-002-0437-xDocument Number: 246364
To evaluate the effects of administration of bromocriptine combined with clomiphene citrate (CC) in CC-resistant patients with polycystic ovary syndrome (PCOS) and normal prolactin (PRL) level. Prospective double-blind, placebo-controlled, randomized. Referral university hospitals. One hundred women with PCOS and normal PRL who failed to ovulate with a routine protocol of CC. Treatment group received 150 mg of CC from day 5 to 9 and 7.5 mg bromocriptine continuously, with hCG 10,000 units on day 16 or 17. Control group received the same protocol of CC combined with placebo. Follicular development, hormonal changes, ovulation rate, pregnancy rate. Follicular development (follicular size greater than 15 mm) was observed in 12 (25.5%) and 8 (15.1%) women in the treatment and placebo group, respectively (p = 0.29). The serum prolactin level was within normal limits in all patients before treatment. After 3 and 6 months of treatment with bromocriptine, there was a significant decrease in serum level of prolactin (p = 0.000001). No significant differences were seen in ovulation, pregnancy rate, or serum levels of FSH, LH, DHEAS, and progesterone between treatment and placebo groups after treatment. The only significant effect of long-term bromocriptine therapy in CC-resistant women with PCOS was to lower the serum PRL concentration. It is also concluded that 10%-15% of patients with PCOS experienced occasional ovulatory cycles and pregnancy whether or not they were on treatment.
Document emailed within 0-6 h
